Kamau Therapeutics co-founders Maria Grazia Roncarolo (L) and Matthew Porteus
December 8, 2023 06:29 AM ESTUpdated 08:53 AM
Startups
R&D
Cell/Gene Tx

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Ayisha Sharma

News Reporter

Ka­mau Ther­a­peu­tics has emerged from stealth mode af­ter ink­ing a deal with Graphite Bio for its genome edit­ing as­sets. Ka­mau’s de­but comes less than a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times